查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1479104

纤维囊性乳房疾病市场：现况分析与预测（2023-2030）

Fibrocystic Breast Condition Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 135 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计 2023 年至 2030 年，纤维囊性乳房疾病市场的复合年增长率约为 5.2%。纤维囊性乳房疾病，也称为纤维囊性变化或纤维囊性乳房，是一种以乳房肿块为特征的非癌性疾病。这种情况受到卵巢分泌的荷尔蒙水平波动的影响。虽然很痛苦，但主要影响30岁至50岁的女性，并持续到更年期和更年期。纤维囊性乳房疾病会增加乳癌的风险。乳癌发生率的增加是促使市场扩张的重要驱动因素。例如，据世界卫生组织称，2022年全球将有约230万名女性被诊断出罹患乳癌，其中67万人将死亡。此外，女性对乳房健康和纤维囊性变化盛行率的认识提高可能会促使更多的人寻求医疗评估和治疗。此外，乳房X光摄影、超音波和MRI等乳房影像技术的进步有助于纤维囊性乳房疾病的早期发现和准确诊断。

根据诊断，市场分为乳房X光检查、超音波、临床乳房检查等。预计临床乳房检查类别在预测期内将占据最高占有率。临床乳房检查可以由医疗保健提供者在各种环境中进行，包括初级保健诊所、妇女健康中心和社区健康活动，使更广泛的人群更容易获得这些检查。医疗保健提供者和组织致力于改进培训计划，以提高临床医生进行彻底、准确的临床乳房检查的熟练程度。这包括正确技术的教育、研究结果的解释以及与患者的沟通。

依治疗方式，纤维囊性乳房疾病市场分为药物、口服避孕药、细针抽吸等。药物可以帮助缓解与纤维囊性乳房疾病相关的症状，例如乳房疼痛、压痛和肿胀。非类固醇类抗发炎药 (NSAID)，例如布洛芬和□普生，通常用于减轻疼痛和发炎。正在进行的临床试验正在评估治疗纤维囊性乳房疾病的新药物和治疗方法的安全性和有效性。这些研究正在探索新的药物配方、标靶治疗和个人化治疗策略，以改善患者的治疗结果。

根据最终用户，纤维囊性乳房疾病市场分为医院、诊所等。其中，预计在预测期内，医院类别对纤维囊性乳房疾病的采用将会增加。医院为纤维囊性乳房疾病患者提供全面的医疗服务，包括诊断评估、治疗、手术介入和术后护理。医院提供的多学科方法使患者能够接受各种医疗保健专业人员（包括内科医生、外科医生、放射科医生、病理学家和护士）的全面协调护理。医院通常设有专门的乳房中心或诊所，并配备了诊断和治疗乳房疾病（包括纤维囊性乳房疾病）的专家的医疗专业人员。

为了更瞭解纤维囊性乳房疾病产业的市场实施情况，市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利、欧洲其他地区）、亚洲太平洋地区（中国、日本、印度、亚太其他地区）和世界其他国家。北美纤维囊性乳房疾病市场的推动因素包括乳癌盛行率不断上升、医疗保健专业人员和一般大众对纤维囊性乳房疾病的认识不断提高、先进技术的市场发展以及治疗选择的数量预计将继续增长。例如，根据 CDC 的数据，2019 年估计有 287,500 例女性新诊断出侵袭性乳癌病例。

市场上的一些主要参与者包括Pfizer Inc, AstraZeneca, DMS Group, Bayer AG, Siemens Healthcare Private Limited, Hologic, Inc., FUJIFILM Healthcare, Allengers, BMI Biomedical International, GE HealthCare.。

目录

第一章 市场介绍

  • 市场定义
  • 主要目标
  • 利益相关者
  • 限制

第二章 研究方法或前提条件

  • 调查过程
  • 调查方法
  • 受访者简介

第三章市场总结

第 4 章执行摘要

第五章 COVID-19 对纤维囊性乳房疾病市场的影响

第六章2020-2030年全球纤维囊性乳房疾病市场收入

第七章 诊断市场洞察

  • 乳腺摄影
  • 超声波
  • 临床乳房检查
  • 其他

第八章 依处理法进行市场分析

  • 药品
  • 口服避孕药
  • 细针抽吸
  • 其他

第 9 章最终用户的市场分析

  • 医院
  • 诊所
  • 其他

第十章区域市场分析

  • 北美纤维囊性乳房疾病市场
    • 美国
    • 加拿大
    • 其他北美
  • 欧洲纤维囊性乳房疾病市场
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区纤维囊性乳房疾病市场
    • 中国
    • 日本
    • 印度
    • 亚太其他地区
  • 其他地区纤维囊性乳房疾病市场

第十一章纤维囊性乳房疾病市场动态

  • 市场驱动力
  • 市场课题
  • 影响分析

第十二章纤维囊性乳房疾病市场机会

第十三章纤维囊性乳房疾病市场趋势与见解

第十四章供需分析

  • 需求面分析
  • 供给侧分析

第十五章价值链分析

第16章价格分析

第17章 竞争场景

  • 竞争格局
    • 波特五力分析

第十八章 公司简介

  • Pfizer Inc
  • AstraZeneca
  • DMS Group
  • Bayer AG
  • Siemens Healthcare Private Limited
  • Hologic, Inc.
  • FUJIFILM Healthcare
  • Allengers
  • BMI Biomedical International
  • GE HealthCare

第19章 免责声明

简介目录
Product Code: UMHE212713

The Fibrocystic breast condition market is expected to register a CAGR of approx. 5.2% over the period of 2023-2030. Fibrocystic breast disease, also known as fibrocystic change or fibrocystic breasts, is a non-cancerous condition characterized by lumpiness in the breasts. The condition is influenced by fluctuating hormone levels produced by the ovaries. Although distressing, it primarily affects women in their 30s and 50s and persists through menopause and perimenopause. The presence of fibrocystic breast disease increases the risk of breast cancer. The increasing occurrence of breast cancer will serve as a significant driver, leading to the expansion of the market. For instance, According to the WHO, Globally, there were approximately 2.3 million women diagnosed with breast cancer in 2022, resulting in 670,000 deaths. Furthermore, greater awareness among women about breast health and the prevalence of fibrocystic changes can lead to more individuals seeking medical evaluation and treatment. Additionally, Technological advancements in breast imaging techniques such as mammography, ultrasound, and MRI contribute to early detection and accurate diagnosis of fibrocystic breast disease.

Based on Diagnosis, the market is segmented into mammogram, ultrasound, clinical breast exam, other. The clinical breast exam category is expected to witness the highest share during the forecast period. Clinical breast exams can be conducted by healthcare providers in various settings, including primary care clinics, women's health centers, and community health events, making them more accessible to a broader population. Healthcare providers and organizations have been focusing on improving training programs for clinicians to enhance their proficiency in conducting thorough and accurate clinical breast exams. This includes providing education on proper technique, interpretation of findings, and communication with patients.

Based on Treatment, the fibrocystic breast condition market has been classified as medication, oral contraceptives, fine-needle aspiration, others. Among them, the myocardial infarction segment is expected to grow at a higher share in the market. Medications can help alleviate symptoms associated with fibrocystic breast disease, such as breast pain, tenderness, and swelling. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or naproxen, are commonly used to reduce pain and inflammation. Ongoing clinical trials are evaluating the safety and efficacy of novel medications and therapeutic approaches for the treatment of fibrocystic breast disease. These studies explore new drug formulations, targeted therapies, and personalized treatment strategies to improve patient outcomes..

Based on the End-User, the Fibrocystic Breast Condition market has been classified into hospital, clinic, others. Among them, the hospitals category is to witness higher adoption of Fibrocystic Breast Condition during the forecast period. Hospitals provide comprehensive medical services, including diagnostic evaluations, medical treatments, surgical interventions, and post-operative care, for individuals with fibrocystic breast disease. The multi-disciplinary approach offered by hospitals ensures that patients receive integrated and coordinated care from various healthcare professionals, such as physicians, surgeons, radiologists, pathologists, and nurses. Hospitals often have specialized breast health centers or clinics staffed with healthcare providers who have expertise in diagnosing and treating breast conditions, including fibrocystic breast disease.

For a better understanding of the market adoption of the Fibrocystic breast condition industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America Fibrocystic Breast Condition market is expected to continue to grow in the coming years, driven by the increasing prevalence of breast cancer and growing awareness of fibrocystic breast condition among healthcare professionals and the general population, development of advanced techniques and the rise in treatment option. For instance, in 2019, according to CDC, An estimated 287,500 new cases of invasive breast cancer were diagnosed in women.

Some of the major players operating in the market include Pfizer Inc, AstraZeneca, DMS Group, Bayer AG, Siemens Healthcare Private Limited, Hologic, Inc., FUJIFILM Healthcare, Allengers, BMI Biomedical International, GE HealthCare.

TABLE OF CONTENTS

1MARKET INTRODUCTION

  • 1.1.Market Definitions
  • 1.2.Main Objective
  • 1.3.Stakeholders
  • 1.4.Limitation

2RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1.Research Process of the Fibrocystic Breast Condition Market
  • 2.2.Research Methodology of the Fibrocystic Breast Condition Market
  • 2.4.Respondent Profile

3MARKET SYNOPSIS

4EXECUTIVE SUMMARY

5IMPACT OF COVID-19 ON THE FIBROCYSTIC BREAST CONDITION MARKET

6GLOBAL FIBROCYSTIC BREAST CONDITION MARKET REVENUE, 2020-2030F

7MARKET INSIGHTS BY DIAGNOSIS

  • 7.1.Mammogram
  • 7.2.Ultrasound
  • 7.3.Clinical Breast Exam
  • 7.4.Other

8MARKET INSIGHTS BY TREATMENT

  • 8.1.Medication
  • 8.2.Oral Contraceptives
  • 8.3.Fine-Needle Aspiration
  • 8.4.Others

9MARKET INSIGHTS BY END-USERS

  • 9.1.Hospital
  • 9.2.Clinic
  • 9.3.Others

10MARKET INSIGHTS BY REGION

  • 10.1NORTH AMERICA FIBROCYSTIC BREAST CONDITION MARKET
    • 10.1.1.U.S.
    • 10.1.2.Canada
    • 10.1.3.Rest of North America
  • 10.2EUROPE FIBROCYSTIC BREAST CONDITION MARKET
    • 10.2.1.Germany
    • 10.2.2.U.K.
    • 10.2.3.France
    • 10.2.4.Italy
    • 10.2.5.Spain
    • 10.2.6.Rest of Europe
  • 10.3ASIA PACIFIC FIBROCYSTIC BREAST CONDITION MARKET
    • 10.3.1.China
    • 10.3.2.Japan
    • 10.3.3.India
    • 10.3.4.Rest of Asia-Pacific
  • 10.4REST OF THE WORLD FIBROCYSTIC BREAST CONDITION MARKET

11FIBROCYSTIC BREAST CONDITION MARKET DYNAMICS

  • 11.1.Market Drivers
  • 11.2.Market Challenges
  • 11.3.Impact Analysis

12FIBROCYSTIC BREAST CONDITION MARKET OPPORTUNITIES

13FIBROCYSTIC BREAST CONDITION MARKET TRENDS & INSIGHTS

14DEMAND AND SUPPLY SIDE ANALYSIS

  • 14.1.Demand Side Analysis
  • 14.2.Supply Side Analysis

15VALUE CHAIN ANALYSIS

16PRICING ANALYSIS

17COMPETITIVE SCENARIO

  • 17.1.Competitive Landscape
    • 17.1.1Porter's Five forces analysis

18COMPANY PROFILED

  • 18.1.Pfizer Inc
  • 18.2.AstraZeneca
  • 18.3.DMS Group
  • 18.4.Bayer AG
  • 18.5.Siemens Healthcare Private Limited
  • 18.6.Hologic, Inc.
  • 18.7.FUJIFILM Healthcare
  • 18.8.Allengers
  • 18.9.BMI Biomedical International
  • 18.10.GE HealthCare

19DISCLAIMER